Hepatocellular Carcinoma (HCC) is one of the most common cancers worldwide with largely unfavorable outcomes due to a lack of effective treatment options for patients in the later state of disease. The gold standard of care for HCC patients with intermediate to locally advanced tumors is transcatheter arterial chemoembolization (TACE), a procedure whereby the tumor is targeted both with local chemotherapy and restriction of local blood supply. TACE procedures are often not effective however, and a need exists to identify patients that will respond to TACE.
NCI scientists have identified a 14-gene signature predictive of response to TACE. This “TACE Navigator Gene Signature Assay” based on a Nanostring platform, is useful in identifying HCC patients in advance who will respond to and have the greatest survival benefit following TACE, and can identify patients who need additional/alternative therapeutic modalities.
- Prognostic test for HCC patient response to TACE procedure
- Companion diagnostic for TACE procedure
- First in class prognostic diagnostic for frontline therapy in highly prevalent HCC
Xin Wei Wang Ph.D. (NCI), Valerie Miller Ph.D. (NCI)
- U.S. Provisional: U.S. Provisional Patent Application Number 62/292,789, Filed 08 Feb 2016
- PCT: PCT Application Number PCT/US2017/016851, Filed 07 Feb 2017
- Foreign Filed: China - Patent Application 201780018693.9, Filed 20 Sep 2018
- Foreign Filed: European Patent - Patent Application 17706618.0, Filed 09 Aug 2018
- U.S. Patent Filed: U.S. Patent Application Number 16/076,239, Filed 07 Aug 2018